Xtx Topco LTD A Tyr Pharma Inc Transaction History

Xtx Topco LTD

$1.3 Billion
Q3 2024

A detailed history of Xtx Topco LTD transactions in A Tyr Pharma Inc stock. As of the latest transaction made, Xtx Topco LTD holds 17,262 shares of LIFE stock, worth $32,107. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,262

Holding current value

$32,107

% of portfolio

0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.51 - $2.24 $26,065 - $38,666	17,262 New	17,262 $32,000
Q1 2024 May 13, 2024	BUY	$1.42 - $2.02 $20,959 - $29,815	14,760 Added 21.53%	83,328 $162,000
Q4 2023 Feb 13, 2024	SELL	$1.11 - $1.51 $5,911 - $8,042	-5,326 Reduced 7.21%	68,568 $96,000
Q3 2023 Nov 13, 2023	SELL	$1.55 - $2.23 $149,623 - $215,264	-96,531 Reduced 56.64%	73,894 $116,000
Q2 2023 Aug 14, 2023	BUY	$1.72 - $2.57 $293,131 - $437,992	170,425 New	170,425 $368,000
Q3 2021 Nov 12, 2021	SELL	$4.22 - $12.48 $51,758 - $153,067	-12,265 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$3.62 - $4.88 $44,399 - $59,853	12,265 New	12,265 $60,000

Others Institutions Holding LIFE

# of Institutions

Shares Held

37.1M

Call Options Held

30.2K

Put Options Held

3.1K

Federated Hermes, Inc. Pittsburgh, PA

14.7M
Shares

$27.3 Million
0.06% of portfolio
Vanguard Group Inc Valley Forge, PA

2.99M
Shares

$5.56 Million
0.0% of portfolio
Tikvah Management LLC Charlotte, NC

2.46M
Shares

$4.58 Million
1.45% of portfolio
Logos Global Management LP San Francisco, CA

2M
Shares

$3.72 Million
0.49% of portfolio
Checkpoint Capital L.P. San Francisco, CA

1.74M
Shares

$3.23 Million
1.52% of portfolio

View Full List

About aTYR PHARMA INC

Ticker LIFE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,625,000
Market Cap $53.2M
Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...

More about LIFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account